CRLF2
CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Acute lymphoblastic leukaemia and 2 more.
Overview
Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2.
CIViC holds 5 clinical evidence items and 0 assertions across 5 variants, naming Sirolimus and JAK Inhibitor I. Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.63, animal model 0.36, somatic mutation 0.80). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Lung Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Acute lymphoblastic leukaemia and 2 more.
- 1 · What it is
CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Acute lymphoblastic leukaemia and 2 more.
- 2 · What goes wrong in cancer
Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5.
- 3 · How drugs use it
No product in this corpus aims at CRLF2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:14281 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9HC73 (protein name, function text, keywords and locations (REST API)); CIViC gene CRLF2 (5 evidence items, 0 assertions, 5 variants; diseases: Acute Lymphoblastic Leukaemia, B-cell Adult Acute Lymphocytic Leukaemia, Childhood B-cell Acute Lymphoblastic Leukaemia, B-lymphoblastic Leukaemia/lymphoma (GraphQL API, CC0)); Open Targets ENSG00000205755 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: melanoma 0.52, skin cancer 0.56, lung cancer 0.53 (GraphQL API, CC0)); IntOGen CRLF2 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2. Implicated in the development of the haematopoietic system. Location: Cell membrane; Secreted (UniProt). Locus Xp22.3 and Yp11.3 (HGNC).
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
- Acute lymphoblastic leukaemia: CIViC evidence names this disease
- Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUAD)
- Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 5 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: B-cell Adult Acute Lymphocytic Leukaemia; Childhood B-cell Acute Lymphoblastic Leukaemia.
Latest papers
topQuery for this target: (TITLE:"CRLF2" OR ABSTRACT:"CRLF2" OR TITLE:"cytokine receptor like factor 2" OR ABSTRACT:"cytokine receptor like factor 2" OR TITLE:"Cytokine receptor-like factor 2" OR ABSTRACT:"Cytokine receptor-like factor 2" OR TITLE:"CRL2" OR ABSTRACT:"CRL2" OR TITLE:"TSLPR" OR ABSTRACT:"TSLPR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CRLF2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetABL2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetNUP98
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Melanoma.
- TargetJAK3
Shares Lung cancer (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
- TargetNKX2-1
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Melanoma.
- TargetACVR1B
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Melanoma.
- TargetIRS4
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Melanoma.
- TargetCDX2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.